Subclinical hypothyroidism, defined as an elevated TSH in the setting of normal thyroid hormone levels, is a common diagnosis in the elderly. The purpose of this study is to examine the hypothalamic-pituitary-thyroid axis in men and women aged 70 years and older with persistent subclinical hypothyroidism. To evaluate the mechanism behind this condition, participants will undergo thyrotropin releasing hormone stimulation testing at 3 visits: baseline and while taking two different thyroid hormone preparations, levothyroxine and liothyronine. The investigators will also assess physiologic responses to these two different thyroid hormone medications to help us understand how the thyroid works in advanced age.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Enrollment
14
Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
University of Pennsylvania
Philadelphia, Pennsylvania, United States
TSH Area Under the Curve
TSH area under the curve within 60 minutes of TRH stimulation when TSH is at goal
Time frame: 0, 5, 10, 15, 20, 30, and 60 min post TRH
TSH Max
The maximum concentration of TSH after TRH stimulation when TSH is at goal
Time frame: Between 0 and 180 min after TRH stimulation
Free T4 Level
Free thyroxine level when TSH level is at goal on therapy.
Time frame: An average of 7 months after initiating therapy
Total T3 Level
Total triiodothyronine level when TSH is at goal on therapy
Time frame: An average of 7 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.